RenovoRx gets USPTO notice of allowance for new RenovoCath cancer drug-delivery patent

• RenovoRx received a USPTO notice of allowance for a new US patent application covering its RenovoCath dual-occlusion cancer drug-delivery catheter.
• The application, titled “Methods and Apparatuses for Delivery of Therapeutic Materials for the Treatment of Cancer,” is expected to expand protection for TAMP.
• RenovoRx said its global IP portfolio now totals 20 issued or allowed patents, with 13 additional patents pending.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. RenovoRx Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608200830PRIMZONEFULLFEED9813319) on August 20, 2026, and is solely responsible for the information contained therein.